Announcement on Inclusion of the Company's Products in the "National Essential Medicines List (2026 Edition)"
Securities code: 600422 Securities abbreviation: Kunyao Group Announcement number: 2026-031
Kunyao Group Co., Ltd.
Announcement on the company's products being newly included in the "National Essential Drugs List (2026 Edition)"
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
According to the "Notice on Issuing the National Essential Drugs List (2026 Edition)" issued by the National Health Commission, the State Administration of Traditional Chinese Medicine, and the State Administration of Disease Control and Prevention (National Health Drug Administration [2026] 17 No.), Kunming Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company")'s main drug Luotai® Xuesaitong Soft Capsules and its holding subsidiary Kunming China Resources Shenghuo Pharmaceutical Co., Ltd. Lijuwang® Xuesaitong Soft Capsules, and Kunming Pharmaceutical Group Xuesaitong Pharmaceutical Co., Ltd. Luotai® Xuesaitong Dropping Pills were newly included in the "National Essential Drugs List (2026 Edition)". Currently, the company has a total of 57 products (84 specifications) included in the "National Essential Medicines List (2026 Edition)", of which 3 products (5 specifications) are newly included. The details of the main drugs newly included in the "National Essential Drugs List (2026 Edition)" are now announced as follows:
1. Basic information on drugs
Drug name: Xuesaitong soft capsules and Xuesaitong dropping pills belong to the category of proprietary Chinese medicines
Drug Classification 1. Internal Medicine (10) Anti-stasis Agents
Drug serial number 109
Soft capsule: 0.55g per capsule Soft capsule: 0.33g per capsule (containing Panax notoginseng total
Dosage form and specification: Dropping pills: Each pill contains notoginseng total soap (containing notoginseng total saponin 60mg), 0.33g (containing notoginseng total saponin)
Glycoside 5mg
100mg) Glycoside 120mg)
Kunming Pharmaceutical Group Xuesaitong Pharmaceutical Co., Ltd. Kunming Pharmaceutical Group Co., Ltd. Kunming China Resources Shenghuo Pharmaceutical Co., Ltd.
Ltd.
It activates blood circulation and removes blood stasis, unblocks the meridians and activates the collaterals. It inhibits blood circulation and removes blood stasis, unblocks the meridians and activates the collaterals. Use it to activate blood circulation, remove blood stasis, unblock meridians and activate meridians. Used for blood stasis
Inhibits platelet aggregation and increases cerebral blood flow in ischemia caused by blood stasis block. Symptoms during the meridian recovery period of stroke with meridian syndrome.
traffic. Used for cerebral collateral stasis, in
Stroke (cerebral infarction): hemiplegia, hemiplegia, crooked mouth and tongue, strong tongue
Function: Indications: wind hemiplegia, heart pulse stasis, chest obstruction and collaterals recovery period, with symptoms such as muteness or muteness in half of the body. Or used for coronary heart disease
Heartache; sequelae of cerebrovascular disease, numbness on one side of the body, crooked speech and tongue
Heart disease, angina pectoris, chest tightness, chest pain, palpitations
Coronary heart disease and angina pectoris have the above syndromes: oblique, astringent speech, etc.
Panic, dark purple tongue or ecchymosis. who.
2. Description of drugs
The company's Xuesaitong series of products, with Panax notoginseng total saponins as the core ingredient, are mainly used to promote blood circulation, remove blood stasis, and unblock meridians and activate meridians. They are representative Chinese patent medicines in the field of cardiovascular and cerebrovascular chronic disease management. A series of evidence-based medical research has been carried out over the years since its launch, and a large amount of evidence-based medical research evidence has been accumulated. It has been included in the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2025)". Xuesaitong soft capsules and dripping pills, which are newly included in the National Essential Drugs List (2026 Edition), have obvious advantages and have a good patient base in cardiovascular and cerebrovascular applications. They have occupied a dominant position in the domestic Panax notoginseng oral drug market for many years. Among them, Xuesaitong Soft Capsules are the exclusive dosage form products of the company and its holding subsidiaries; in 2024, Xuesaitong Soft Capsules were awarded the "Champion Product" of the "Manufacturing Individual Champion Enterprise" by the Ministry of Industry and Information Technology. In 2025, the company's sales revenue of Xuesaitong soft capsules and dripping pills will be approximately 902.4225 million yuan, accounting for 13.72% of the company's operating revenue.
Currently, the aging of the domestic population continues to accelerate, and the market demand for chronic disease management and the health of seniors is steadily expanding. Products represented by Panax notoginseng extract have broad usage scenarios among the senior population. The company has built a complete industrial chain covering Panax notoginseng GAP cultivation and slice processing to Panax notoginseng total saponin extraction, preparation production, and professional marketing and promotion. Since establishing its strategic positioning as "a leader in the silver-haired health industry", the company has deeply explored the entire Panax notoginseng industry chain and continued to improve its industrial layout around the fields of aging health and chronic disease management. The new inclusion of Xuesaitong soft capsules and dripping pills into the "National Essential Drugs List (2026 Edition)" is not only a high degree of recognition of the clinical value of the product and evidence-based medical evidence, but also a key implementation of the company's silver health strategy in building the Panax notoginseng industry chain and deepening the field of cardio-cerebral chronic disease management. The new inclusion of core products in the essential medicine catalog will further enhance the accessibility of products in grassroots and community medical scenarios, allow high-quality proprietary Chinese medicines to benefit more senior groups, effectively reduce patients’ medication burden, and contribute to the improvement of the national comprehensive chronic disease prevention and control system and the construction of a healthy aging society.
3. Impact on the company and risk warning
After the Xuesaitong soft capsules and dripping pills are newly included in the "National Essential Drugs List (2026 Edition)", it will effectively help product market expansion and provide support for subsequent product sales; however, affected by multiple factors such as industry policies and market environment, there is still uncertainty in the future sales of the product. Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Kunming Pharmaceutical Group Co., Ltd.
July 11, 2026